Confessions of an innovatorThe development of many innovations in ophthalmology did not happen in a straightforward manner as shown in these case examples.
Fighting against glaucoma-therapy related ocular surface diseaseOcular surface disease (OSD) and dry eye disease (DED) are very common problems in the elderly, and they both considerably decrease vision-related quality of life.
Bimatoprost insert offers noninvasive platform for early glaucoma patients A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.
How 24-hour IOP measurements vary with glaucoma treatmentClinicians should take into account the way IOP varies over the course of 24 hours depending on the glaucoma treatment used, according to the authors of a new literature review.
Taking a closer look at low-tension glaucoma risk factors, treatment guidelinesA reasonable goal for patients with low-tension glaucoma patients is an IOP that’s 30% below the untreated baseline. However, some patients will continue to progress and may require single-digit target IOP goals.
Long-term implant showing potential in glaucoma therapyAn extended-release therapy that encapsulates travoprost in an intracameral implant showed a statistically significant and clinically meaningful reduction in IOP with results comparable to topical once-daily travoprost ophthalmic solution, said Tom R. Walters, MD, Texan Eye, Austin.
Advances in wound healing tools and techniquesNew wound-healing tools arising from evolving knowledge of the wound-healing process include drugs, debridement techniques, advanced skin grafting tools and stem cell delivery strategies.
Latanoprostene bunod shows promise in patients with open-angle glaucoma, ocular hypertensionFindings from the CONSTELLATION study show that once-daily latanoprostene bunod lowered IOP more than twice-daily timolol in patients with open-angle glaucoma or ocular hypertension.